Paclitaxel treatment reduces neointimal hyperplasia in cultured human saphenous veins

European Journal of Cardio-thoracic Surgery

Volumn 32, Issue 6, 2007, Pages 906-911

  Schachner, Thomas ^a   Steger, Christina ^b   Heiss, Simone ^c   Bonaros, Nikolaos ^a   Sterlacci, William ^b   Laufer, Guenther ^a   Bonatti, Johannes ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF INNSBRUCK   (Austria)

^c NONE   (Austria)

Author keywords

Coronary surgery; Intimal hyperplasia; Neointima; Paclitaxel; Saphenous vein; Vein graft

Indexed keywords

COLLAGEN FIBER; EBETAXEL; KI 67 ANTIGEN; PACLITAXEL; SMOOTH MUSCLE ACTIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; CORONARY ARTERY BYPASS GRAFT; ELASTIC FIBER; FEMALE; HUMAN; HUMAN TISSUE; MALE; ORGAN CULTURE; PRIORITY JOURNAL; SAPHENOUS VEIN;

ACTINS; AGED; AGED, 80 AND OVER; CORONARY ARTERY BYPASS; DESMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-ELUTING STENTS; ELASTIC TISSUE; FEMALE; HUMANS; HYPERPLASIA; KI-67 ANTIGEN; MALE; MIDDLE AGED; ORGAN CULTURE TECHNIQUES; PACLITAXEL; SAPHENOUS VEIN; TUBULIN MODULATORS; TUNICA INTIMA;

EID: 35948961115     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2007.09.015     Document Type: Article

References (20)

1. Walter J., and Magometschnigg H. The role of vein grafts in peripheral vascular disease and carotid artery disease. Eur Surg 39 (2007) 76-82
2. Bonatti J., Oberhuber A., Schachner T., Zou Y., Hammerer-Lercher A., Mittermair R., and Laufer G. Neointimal hyperplasia in coronary vein grafts: pathophysiology and prevention of a significant clinical problem. Heart Surg Forum 7 1 (2004) 72-87
3. Schachner T., Laufer G., and Bonatti J. The role of vein grafts in coronary surgery. Eur Surg 39 (2007) 72-75
4. Motwani J.G., and Topol E.J. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation 97 9 (1998) 916-931
5. Akowuah E.F., Sheridan P.J., Cooper G.J., and Newman C. Preventing saphenous vein graft failure: does gene therapy have a role?. Ann Thorac Surg 76 (2003) 959-966
6. Schachner T. Pharmacological inhibition of vein graft neointimal hyperplasia. J Thorac Cardiovasc Surg 131 (2006) 1065-1072
7. Schachner T., Laufer G., and Bonatti J. In vivo (animal) models of vein graft disease. Eur J Cardiothorac Surg 30 (2006) 451-463
8. Schachner T., Zou Y., Oberhuber A., Tzankov A., Mairinger T., Laufer G., and Bonatti J.O. Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann Thorac Surg 77 (2004) 1580-1585
9. Schachner T., Heiss S., Zipponi D., Tzankov A., Bernecker O., Kroell A., Laufer G., and Bonatti J. Perivascular treatment with Azathioprine reduces neointimal hyperplasia in experimental vein grafts. Heart Surg Forum 9 (2006) E515-E517
10. Schachner T., Zou Y., Oberhuber A., Mairinger T., Tzankov A., Laufer G., Ott H., and Bonatti J. Perivascular application of C-type natriuretic peptide attenuates neointimal hyperplasia in experimental vein grafts. Eur J Cardiothorac Surg 25 (2004) 290-585
11. Herdeg C., Oberhoff M., Baumbach A., Blattner A., Axel D.I., Schroeder S., Heinle H., and Karsch K.R. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 35 (2000) 1969-1976
12. Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M, Nater C, Hruban RH, Rezai B, Abella BS, Bunge KE, Kinsella JL, Sollott SJ, Lakatta EG, Brinker JA, Hunter WL, Froehlich JP. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis circulation 2001;103:2289-95.
13. Park S., Shim W.H., Ho D.S., Raizner A.E., Park S., Hong M., Lee C.W., Choi D., Jang Y., Lam R., Weissman N.J., and Mintz G.S. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med 348 (2003) 1537-1545
14. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J., Turco M., Caputo R., Bergin P., Greenberg J., Popma J.J., Russell M.E., and for the TAXUS-IV Investigators. A polymer-B based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
15. Axel D.I., Kunert W., Göggelmann C., Oberhoff M., Herdeg C., Küttner A., Wild D.H., Brehm B.R., Riessen R., Köveker G., and Karsch K.R. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96 (1997) 636-645
16. Johnson J.L., van Eys G.J., Angelini G.D., and George S.J. Injury induces dedifferentiation of smooth muscle cells and increased matrix-degrading metalloproteinase activity in human saphenous vein. Arterioscler Thromb Vasc Biol 21 (2001) 1146-1151
17. Galea J., Armstrong J., Francis S.E., Cooper G., Crossman D.C., and Holt C.M. Alterations in c-fos expression, cell proliferation and apoptosis in pressure distended human saphenous vein. Cardiovasc Res 44 (1999) 436-448
18. Porter K.E., Varty K., Jones L., Bel P.P.R., and London N.J. Human saphenous vein organ culture: a useful model of intimal hyperplasia?. Eur J Vasc Endovasc Surg 11 (1996) 48-58
19. Huang B., Dreyer T., Heidt M., Yud J.C., Philipp M., Hehrlein F.W., Katz N., and Al-Fakhri N. Insulin and local growth factor PDGF induce intimal hyperplasia in bypass graft culture models of saphenous vein and internal mammary artery. Eur J Cardiothorac Surg 21 (2002) 1002-1008
20. Aguilera C.M., George S.J., Johnson J.L., and Newby A.C. Relationship between type IV collagen degradation, metalloproteinase activity and smooth muscle cell migration and proliferation in cultured human saphenous vein. Cardiovasc Res 58 (2003) 679-688